Singapore Proposal on New Regulatory Framework for Complementary Health Products

Singapore’s Health Sciences Authority (HSA) has launched a public consultation on a proposed regulatory framework for Complementary Health Products (CHPs) under the Health Products Act (HPA). The consultation is open until 29 July 2026 and covers a wide range of products including health supplements.

The proposal forms part of Singapore’s ongoing effort to transfer the regulation of CHPs from the Medicines Act to the Health Products Act, with full implementation targeted by the end of 2028. While maintaining the current light-touch approach to pre-market regulation, HSA is proposing enhanced controls to strengthen consumer protection and improve regulatory oversight.

Key proposed changes include mandatory product notification requirements, strengthened safety, quality and labelling standards, enhanced record-keeping and adverse event reporting obligations, and increased regulatory powers to address non-compliance. The new framework is also intended to support more effective post-market surveillance and product traceability.

According to HSA, CHPs generally have a lower-risk safety profile and are currently not subject to pre-market product evaluation or licensing requirements. The proposed framework seeks to preserve access to these products while providing stronger safeguards for consumers and clearer obligations for industry operators.